Bull CaseOne of the biggest highlights of the quarter for Abbott Laboratories (NYSE:ABT) was its diagnostics segment. This suggests that customer demand has been delayed rather than cancelled, potentially supporting future revenue growth. Bear CaseHowever, Danaher Corporation (NYSE:DHR) reported weaker-than-expected revenue in its biotechnology business and cut its full-year core revenue growth outlook. For Danaher Corporation (NYSE:DHR), investors should watch bioprocessing order growth over the coming quarters. Management also expects 3%-4% core revenue growth for fiscal 2026, making execution in its Life Sciences segment an important factor to monitor.